Aloisine A

CAT: 0804-HY-112363-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-112363-01Size:5 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Aloisine A (RP107) is a a potent cyclin-dependent kinase (CDK) inhibitor with IC50s of 0.15 μM, 0.12 μM, 0.4 μM, 0.16 μM for CDK1/cyclin B, CDK2/cyclin A, CDK2/cyclin E, CDK5/p35, respectively. Aloisine A ininhibits GSK-3α (IC50=0.5 μM) and GSK-3β (IC50=1.5 μM) . Aloisine A stimulates wild-type CFTR and mutated CFTR, with submicromolar affinity by a cAMP-independent mechanism. Aloisine A has the potential for CFTR-related diseases, including cystic fibrosis research[1][2].
CAS Number
[496864-16-5]
Product Name Alternative
RP107
UNSPSC
12352005
Hazard Statement
H302-H312-H332
Target
CDK; CFTR; ERK; GSK-3; JNK
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; MAPK/ERK Pathway; Membrane Transporter/Ion Channel; PI3K/Akt/mTOR; Stem Cell/Wnt
Applications
COVID-19-anti-virus
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/aloisine-a.html
Solubility
10 mM in DMSO
Smiles
OC1=CC=C(C2=C(CCCC)C3=NC=CN=C3N2)C=C1
Molecular Formula
C16H17N3O
Molecular Weight
267.33
Precautions
P261-P264-P270-P271-P280-P302+P352-P304+P340-P330-P363-P501
References & Citations
[1]Yvette Mettey, et al. Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects. J Med Chem. 2003 Jan 16;46 (2) :222-36.|[2]Sabrina Noel, et al. Discovery of pyrrolo[2,3-b]pyrazines derivatives as submicromolar affinity activators of wild type, G551D, and F508del cystic fibrosis transmembrane conductance regulator chloride channels. J Pharmacol Exp Ther. 2006 Oct;319 (1) :349-59.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
CDK1; CDK2; CDK5; ERK1; ERK2; GSK-3α; GSK-3β; JNK

Related Products

Popular Products